Xenon Pharmaceuticals Inc (XENE-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr03/2026	Next Qtr06/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	$-1.17	$-1.15	$-4.83	$-4.72
Number of Estimates	8	8	11	10
High Estimate	$-1.07	$-1.05	$-4.47	$-3.54
Low Estimate	$-1.32	$-1.26	$-5.20	$-6.05
Prior Year	$-0.83	$-1.07	$-4.36	$-4.83
Growth Rate Est. (year over year)	-40.96%	-7.48%	-10.78%	+2.28%

Earnings History - Surprises*

	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025
Reported	$-1.31	$-1.15	$-1.07	$-0.83
Estimate	$-1.20	$-1.16	$-1.03	$-0.94
Difference	-0.11	+0.01	-0.04	+0.11
Surprise	-9.17%	+0.86%	-3.88%	+11.70%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.81

3 Mths Ago21

4.81

2 Mths Ago21

4.82

1 Mth Ago22

4.82

Current22

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	21	21	22	22
	18 2	18 2	19 2	19 2
Holds	1	1	1	1

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Rogers reports higher profit, updates outlook on lower capital expenditures

Bullish on Pembina Pipeline Corp.

How investors should digest the stock market’s ‘sugar high’

Market Factors: Top picks, sector review for income-heavy utilities sector

The most oversold and overbought stocks on the TSX

The highest-yielding stocks on the TSX, plus risk data

Barlow’s Research Roundup: These stocks are biggest winners from oil price volatility

It’s not just Allbirds - another meme-stock season is on the horizon, Vanda Research says